FcZero-rAb™ PE Anti-Human CD85j / LILRB1 (GHI/75) Rabbit IgG Recombinant Antibody
CD85j / LILRB1 Recombinant Antibody for FC
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
FC
Conjugate
PE Fluorescent Dye
CloneNo.
GHI/75
Cat no : PE-FcA65623
Synonyms
Validation Data Gallery
Tested Applications
Positive FC detected in | human PBMCs |
Recommended dilution
Application | Dilution |
---|---|
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
PE-FcA65623 targets CD85j / LILRB1 in FC applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Recombinant |
Type | Antibody |
Immunogen | Human Hairy Cell Leukemia Spleen Cells 相同性解析による交差性が予測される生物種 |
Full Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 |
Calculated molecular weight | 71 kDa |
GenBank accession number | BC015731 |
Gene symbol | LILRB1 |
Gene ID (NCBI) | 10859 |
Conjugate | PE Fluorescent Dye |
Excitation/Emission maxima wavelengths | 496 nm, 565 nm / 578 nm |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA. |
Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
LILRB1, also named as CD85j or ILT2, includes four C2 Ig domains binding HLA class I molecules in the extracellular region and a cytoplasmic domain containing four immunoreceptor tyrosine-based inhibition motifs (ITIM). LILRB1 is a surface glycoprotein detected on the surface of B cells, monocytes, dendritic cells, T cells and NK cells.
Protocols
Product Specific Protocols | |
---|---|
FC protocol for PE CD85j / LILRB1 antibody PE-FcA65623 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |